RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union)

Structure/Sequence

Sequence Code 775236081H

Source: *****

Sequence Code 775236082L

Source: *****

Clinical Trials associated with Lacutamab

NCT05321147

/ CompletedPhase 1

A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.

Start Date17 Mar 2022

Sponsor / Collaborator

Innate Pharma SA

NCT04984837

/ Active, not recruitingPhase 2IIT

A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma

This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL).
The design is non comparative meaning that non comparison between arms will be performed as the control arm will ensure that the assumptions used for sample size calculation are verified. For that reason, randomization is unbalanced in favor of the experimental arm (2:1).

Start Date05 Oct 2021

Sponsor / Collaborator

Le LYSARC

[+1]

NCT03902184

/ CompletedPhase 2

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

Start Date22 May 2019

Sponsor / Collaborator

Innate Pharma SA

100 Clinical Results associated with Lacutamab

100 Translational Medicine associated with Lacutamab

100 Patents (Medical) associated with Lacutamab

Literatures (Medical) associated with Lacutamab

01 Dec 2025·AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Advancements in Cutaneous T-Cell Lymphoma Treatment

Review

Author: Jamil, Abdur ; Hameed, Fatima ; Qureshi, Zaheer ; Kahlon, Navkirat

Objectives::

The non-Hodgkin lymphoma class known as cutaneous T-cell lymphomas (CTCLs) is uncommon and diverse, mainly affecting the skin. The prognosis is dismal, and despite recent breakthroughs, few treatment options are available for advanced-stage disease. This narrative review outlines the current state of care for CTCLs, emphasizing innovative immunotherapies, targeted medicines, combination approaches, and epigenetic modifiers.

Methods::

This paper was conducted to summarize the newer approaches to treating CTCL, with a literature search spanning PubMed, Science Direct, and Cochrane databases that identified articles reporting emerging treatments. Selected articles were categorized into sections to summarize pertinent results in a narrative report.

Results::

Extracorporeal photopheresis with mogamulizumab, a monoclonal antibody targeting CCR4, has shown promise in treating skin and blood involvement while maintaining a good safety record. Additional treatments that have been highlighted include the antibody-drug combination brentuximab vedotin, which targets CD30; checkpoint inhibitors like pembrolizumab and durvalumab; and new medicines, including CD47 inhibitor TTI-621, IL-2/IL-9/IL-15 signaling inhibitor BNZ-1, pegylated interferon alpha-2a, and anti-KIR3DL2 antibody IPH4102. Even though the early clinical trial results for these novel treatments have been positive, more extensive research is required to determine the safety and efficacy of the treatments.

Conclusions::

This review emphasizes the necessity for ongoing research and individualized treatment plans while highlighting the promise of these cutting-edge techniques to enhance outcomes for patients with advanced CTCL.

03 Oct 2025·Expert Review of Anticancer Therapy

New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update

Review

Author: Suzanne Xu ; Francine Foss ; Tarsheen Sethi ; Amrita Goyal-O’Leary

INTRODUCTION:

Mycosis fungoides (MF) and Sézary syndrome (SS) are T cell lymphomas of the skin with prolonged clinical course requiring multiple lines of therapy in a patient's lifetime. The treatment of MF/SS with available agents is complicated by the differential response in skin, lymph nodes, and blood. Advances in understanding the biology of the disease have led to therapies with better efficacy and improvement in quality of life for patients with relapsed and refractory disease.

AREAS COVERED:

This review will outline clinical data for novel biologics including monoclonal antibodies, small molecule inhibitors, and immunotherapeutic approaches such as CAR-T and bispecific antibodies.

EXPERT OPINION:

Nonchemotherapy options which avoid generalized immunosuppression are a preferred consideration for patients with MF/SS, given the compromised skin integument of these patients. Targeted therapies including brentuximab vedotin, lacutamab, denileukin diftitox, and mogamulizumab have shown activity in registrational trials. Novel agents which modulate tumor microenvironment and upregulate tumor-specific immune responses have been in clinical trials, including bispecific antibodies recruiting immune effectors, agents eradicating suppressive microenvironments, and engineered T cells targeting tumor epitopes. Checkpoint inhibitors may play a role in MF/SS but their role has not been well defined, and they may induce hyper progression.

20 Jun 2025·BRITISH JOURNAL OF DERMATOLOGY

Therapeutic advances for cutaneous T-cell lymphoma

Review

Author: Bagot, Martine

Abstract:

Cutaneous T-cell lymphomas (CTCLs) are a group of rare and heterogenous diseases. There is currently no curative treatment for patients with advanced mycosis fungoides (MF) and Sézary syndrome (SS). The European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of MF/SS have been updated and focus on recently available treatments. Peginterferon, a new form of interferon, has a favourable risk–benefit profile for the treatment of patients with CTCL. Recently approved monoclonal antibodies (mABs) have completely modified the treatment algorithm of advanced CTCL treatment. Brentuximab vedotin is very efficient for tumours and transformed MF. Mogamulizumab can induce long-term remission in patients with SS. An international trial of lacutamab has recently been completed, for both SS and MF. Numerous novel targets have been identified, and several new mABs have been shown to be able to enhance specific immune responses and to induce targeted antibody-dependent cytotoxicity and cytophagocytosis. These new antibodies warrant further evaluation in controlled trials. Kinase inhibitors and chimeric antigen receptor T-cell therapy are promising new treatments. Finally, recent studies have demonstrated that allogeneic haematopoietic stem-cell transplantation can increase survival and quality of life in patients with advanced CTCL.

147

News (Medical) associated with Lacutamab

20 Oct 2026

·www.biospace.com

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech --Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Stéphanie Cornen, Vice President, Investor Relations and Communications Frédéric Lombard, Senior Vice President, Chief Financial Officer Event details Date and time: November 5, 2026 at 2:00 p.m. CET / 8:00 a.m. ET Webcast link: Click here Conference call link: Click here This information is also available on the Investors section of the Innate Pharma website, . A replay of the webcast will be available on the Company website for 90 days following the event. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC). Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X . Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website ( ) or on Innate Pharma’s website ( ), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Contacts Stéphanie Cornen stephanie.cornen@innate-pharma.fr Investor Relations investors@innate-pharma.fr Media communication@innate-pharma.fr

ImmunotherapyADC

17 Sep 2026

·www.prnewswire.com

Sobi and Innate announce partnership is now effective following completion of closing conditions

STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. On the 10th of August 2026, Sobi entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL with first patient expected Q1 2027. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma to support a planned accelerated approval filing for Sézary syndrome. The planned TELLOMAK-3 study will support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialise lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results. Under the terms of the agreement, Sobi will pay Innate Pharma USD 75 million upon the partnership becoming effective. Innate will be eligible to receive up to a further USD 40 million in respect of near-term development milestones connected to Sezary syndrome. Additionally, Innate will be eligible to receive up to USD 465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. Innate will be eligible to receive tiered double-digit royalties on net sales. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. Gerard Tobin Head of Investor Relations This information was brought to you by Cision . The following files are available for download: 21% more press release views with Request a Demo

Phase 3License out/inAccelerated Approval

17 Sep 2026

·www.biospace.com

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027 MARSEILLE, France--(BUSINESS WIRE)-- $IPH #ADC --Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027. Under the agreement, Innate is conducting the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma. The TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC). Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X . Information about Innate Pharma shares ISIN code: FR0010331421 Ticker code: Euronext Paris: IPH | Nasdaq: IPHA LEI: 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Contacts Stéphanie Cornen VP, Investor Relations & Corporate Communications stephanie.cornen@innate-pharma.fr Investor Relations investors@innate-pharma.fr Media communication@innate-pharma.fr

100 Deals associated with Lacutamab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15322

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral T-Cell Lymphoma	Phase 2	Belgium	Innate Pharma SA	05 Oct 2021
Peripheral T-Cell Lymphoma	Phase 2	France	Innate Pharma SA	05 Oct 2021
Peripheral T-Cell Lymphoma	Phase 2	Germany	Innate Pharma SA	05 Oct 2021
Peripheral T-Cell Lymphoma	Phase 2	Spain	Innate Pharma SA	05 Oct 2021
Sezary Syndrome	Phase 2	United States	Innate Pharma SA	22 May 2019
Sezary Syndrome	Phase 2	Austria	Innate Pharma SA	22 May 2019
Sezary Syndrome	Phase 2	Belgium	Innate Pharma SA	22 May 2019
Sezary Syndrome	Phase 2	France	Innate Pharma SA	22 May 2019
Sezary Syndrome	Phase 2	Germany	Innate Pharma SA	22 May 2019
Sezary Syndrome	Phase 2	Italy	Innate Pharma SA	22 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03902184 (TELLOMAK, ASCO2025 \| ICML2025)	Phase 2	Mycosis Fungoides KIR3DL2	107	Lacutamab 750 mg	yywfolqgni(fymmsmvseb) = feopxkihta hhafswyffm (zuajeysxgr, 13.2 - 28.1) View more	Positive	30 May 2025
NCT03902184 (TELLOMAK, ASCO2025 \| ICML2025)	Phase 2	Sezary Syndrome KIR3DL2	63	Lacutamab 750 mg	pfqjcyzudk(pgtleeebmi) = fpkqdnywri znydokjwdv (eqzrkahjtm, 31.4 - 55.1) View more	Positive	30 May 2025
NCT03902184 (TELLOMAK, ASCO2024) Manual	Phase 2	Mycosis Fungoides KIR3DL2 Positive	107	Lacutamab 750 mg	dhtfrfpkai(wjgtqxfntm) = yomoepixke mpjdohbicm (mmgudqfajj, 10.9 - 25.0) View more	Positive	24 May 2024
NCT03902184 (TELLOMAK, ASCO2024) Manual	Phase 2	Mycosis Fungoides KIR3DL2 Positive	107	Lacutamab 750 mg (KIR3DL2 ≥1%)	dhtfrfpkai(wjgtqxfntm) = hkbwscwvfx mpjdohbicm (mmgudqfajj, 11.7 - 34.3) View more	Positive	24 May 2024
NCT03902184 (Tellomak Phase 2 Trial, ASH2023)	Phase 2	Sezary Syndrome	56	Lacutamab 750 mg	kagjciokrk(tbypkkabqt) = zrwaocufzx byilgdihol (kpcjrpbmxk, 26.0 - 50.6) View more	-	09 Dec 2023
NCT03902184 (TELLOMAK, EORTC_CLTG2023)	Phase 2	Mycosis Fungoides KIR3DL2	39	Lacutamab	fwklwptssa(yxrahortyo) = gtndsvniuo yadjpyrhnb (xajziwcqom, 13.8 - 50.0)	Positive	21 Sep 2023
NCT03902184 (TELLOMAK, ICML2023)	Phase 2	Mycosis Fungoides KIR3DL2	39	Lacutamab	rsvwclrvnz(jebpucdnlm) = sbjvlpfyfx lakxpblhtg (lkbavnufda, 24.5 - 63.5)	Positive	09 Jun 2023
NCT03902184 (Tellomak, ASH 12022 \| ASH 22022) Manual	Phase 2	Sezary Syndrome	37	lacutamab	spvxsvvidl(aoivjojoss) = pnlujpfnge tovjgjjcfv (zllygbuybl, 11.4 - 37.2) View more	Positive	15 Nov 2022
EORTC_CLTG2021 \| ICML2021	Not Applicable	Mycosis Fungoides	-	Lacutamab 750 mg	sxinhrfbuw(oxnimmoqjg) = N=6, 25%; TR: 2 uqzbepqgjk (fjshwaedzx ) View more	-	14 Oct 2021
NCT03902184 (TELLOMAK, Corporate Publications) Manual	Phase 2	Mycosis Fungoides	36	Lacutamab (KIR3DL2-expressing cohort)	yhynrdzhzf(dxfhqpsayv) = 1 CR，10 PR opkmstiuqw (zszptnhfcq ) View more	Positive	22 Jun 2021
NCT03902184 (TELLOMAK, Corporate Publications) Manual	Phase 2	Mycosis Fungoides	36	Lacutamab		Positive	22 Jun 2021
ICML2021 \| EORTC_CLTG2021	Phase 2	Mycosis Fungoides KIR3DL2 expressing	24	Lacutamab 750 mg	oltrwvhgfr(ezealuqjjo) = tbmervryjg ipuzyqwimr (ddnfzcmhyg ) View more	Positive	17 Jun 2021
ICML2021 \| EORTC_CLTG2021	Phase 2	Mycosis Fungoides KIR3DL2 expressing	24	Placebo	khfdxvxtvp(aufrkpkwyz) = alisnlbikv sydkpuimwa (tnpzrvogit )	Positive	17 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis